Tinea pedis (Athlete Foot) - Pipeline Review, H1 2020

June 2020 | 32 pages | ID: TC4F7B8E9EBEN
Global Markets Direct

Abstracts

Tinea pedis (Athlete Foot) - Pipeline Review, H1 2020

SUMMARY

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Tinea Pedis (Athlete Foot) - Pipeline Review, H1 2020, provides an overview of the Tinea Pedis (Athlete Foot) (Infectious Disease) pipeline landscape.
Athlete's foot, also known as tinea pedis, is a common foot infection caused by fungi called dermatophytes. Symptoms include dry flaking skin on the soles of the feet, unpleasant foot odour and small itchy bubbles or blisters on the soles of the feet. Treatment includes antifungal medicines.

REPORT HIGHLIGHTS

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Tinea Pedis (Athlete Foot) - Pipeline Review, H1 2020, provides comprehensive information on the therapeutics under development for Tinea Pedis (Athlete Foot) (Infectious Disease), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.
The Tinea Pedis (Athlete Foot) (Infectious Disease) pipeline guide also reviews of key players involved in therapeutic development for Tinea Pedis (Athlete Foot) and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies/Universities/Institutes, the molecules developed by Companies in Phase III, Phase II and Phase I stages are 1, 3 and 1 respectively.
Tinea Pedis (Athlete Foot) (Infectious Disease) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content/sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

SCOPE

• The pipeline guide provides a snapshot of the global therapeutic landscape of Tinea Pedis (Athlete Foot) (Infectious Disease).
• The pipeline guide reviews pipeline therapeutics for Tinea Pedis (Athlete Foot) (Infectious Disease) by companies and universities/research institutes based on information derived from company and industry-specific sources.
• The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
• The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
• The pipeline guide reviews key companies involved in Tinea Pedis (Athlete Foot) (Infectious Disease) therapeutics and enlists all their major and minor projects.
• The pipeline guide evaluates Tinea Pedis (Athlete Foot) (Infectious Disease) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
• The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
• The pipeline guide reviews latest news related to pipeline therapeutics for Tinea Pedis (Athlete Foot) (Infectious Disease)

REASONS TO BUY

• Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
• Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
• Find and recognize significant and varied types of therapeutics under development for Tinea Pedis (Athlete Foot) (Infectious Disease).
• Classify potential new clients or partners in the target demographic.
• Develop tactical initiatives by understanding the focus areas of leading companies.
• Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
• Formulate corrective measures for pipeline projects by understanding Tinea Pedis (Athlete Foot) (Infectious Disease) pipeline depth and focus of Indication therapeutics.
• Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
• Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Contents

Introduction
Global Markets Direct Report Coverage
Tinea Pedis (Athlete Foot) - Overview
Tinea Pedis (Athlete Foot) - Therapeutics Development
Pipeline Overview
Pipeline by Companies
Products under Development by Companies
Tinea Pedis (Athlete Foot) - Therapeutics Assessment
Assessment by Target
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Tinea Pedis (Athlete Foot) - Companies Involved in Therapeutics Development
Biolab Farmaceutica Ltda
Blueberry Therapeutics Ltd
Broda Tech LLC
DermBiont Inc
Sanotize Research And Development Corp
Tinea Pedis (Athlete Foot) - Drug Profiles
dapaconazole - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
DBI-001 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
NORS-6491 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
terbinafine hydrochloride - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
terbinafine hydrochloride - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Tinea Pedis (Athlete Foot) - Dormant Projects
Tinea Pedis (Athlete Foot) - Product Development Milestones
Featured News & Press Releases
Oct 22, 2019: DermBiont announces positive data from phase 2a clinical trial and start of phase 2b clinical trial for Athlete’s Foot with a topical live biotherapeutic
Mar 13, 2019: DermBiont begins Phase 2 clinical trial for athlete's foot with a live bacterial topical probiotic
Nov 23, 2018: Blueberry reports positive results from Phase I/II BB2603 trial
Apr 26, 2017: Blueberry Therapeutics commence Phase I/II clinical trial of lead product BB2603
Apr 04, 2017: Mike Davies presents at the "Adaptive Designs in Clinical Trials" conference
Feb 28, 2017: Blueberry Therapeutics gains final approval for its first clinical trial
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer

List Of Tables

LIST OF TABLES

Number of Products under Development for Tinea Pedis (Athlete Foot), H1 2020
Number of Products under Development by Companies, H1 2020
Products under Development by Companies, H1 2020
Number of Products by Stage and Target, H1 2020
Number of Products by Stage and Mechanism of Action, H1 2020
Number of Products by Stage and Route of Administration, H1 2020
Number of Products by Stage and Molecule Type, H1 2020
Tinea Pedis (Athlete Foot) - Pipeline by Biolab Farmaceutica Ltda, H1 2020
Tinea Pedis (Athlete Foot) - Pipeline by Blueberry Therapeutics Ltd, H1 2020
Tinea Pedis (Athlete Foot) - Pipeline by Broda Tech LLC, H1 2020
Tinea Pedis (Athlete Foot) - Pipeline by DermBiont Inc, H1 2020
Tinea Pedis (Athlete Foot) - Pipeline by Sanotize Research And Development Corp, H1 2020
Tinea Pedis (Athlete Foot) - Dormant Projects, H1 2020

List Of Figures

LIST OF FIGURES

Number of Products under Development for Tinea Pedis (Athlete Foot), H1 2020
Number of Products under Development by Companies, H1 2020
Number of Products by Top 10 Targets, H1 2020
Number of Products by Stage and Top 10 Targets, H1 2020
Number of Products by Top 10 Mechanism of Actions, H1 2020
Number of Products by Stage and Top 10 Mechanism of Actions, H1 2020
Number of Products by Top 10 Routes of Administration, H1 2020
Number of Products by Stage and Top 10 Routes of Administration, H1 2020
Number of Products by Top 10 Molecule Types, H1 2020
Number of Products by Stage and Top 10 Molecule Types, H1 2020

COMPANIES MENTIONED

Biolab Farmaceutica Ltda
Blueberry Therapeutics Ltd
Broda Tech LLC
DermBiont Inc
Sanotize Research And Development Corp